Trials / Completed
CompletedNCT02629003
[11C]Cimbi-36 Dosimetry
Evaluation of Radiation Dose for [11C]Cimbi-36
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Gitte Moos Knudsen · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine the dosimetry for the Positron Emission Tomography (PET) tracer \[11C\]Cimbi-36 in two different Carbon-11 labelling positions. This information will contribute to determining whether \[11C\]Cimbi-36 can be optimized by changing the C-11 labelling position.
Detailed description
Healthy subjects wil undergo a whole-body Positron Emission Tomography (PET) scan with the Serotonin 2A Receptor (5-HT2A) radioligand \[11C\]Cimbi-36 or \[11C\]Cimbi-36-5 to determine the effective radiation dose and radiation dose for selected organs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [11C]Cimbi-36 | |
| DRUG | [11C]Cimbi-36-5 |
Timeline
- Start date
- 2015-12-01
- Primary completion
- 2018-10-10
- Completion
- 2018-10-10
- First posted
- 2015-12-11
- Last updated
- 2019-03-26
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT02629003. Inclusion in this directory is not an endorsement.